Specifically, in a cohort of 20 primary GBMs, tumours targeting HER2 or IL13Rα2 alone had a near-complete eradication rate of 60%−70%, whereas tumours targeting both HER2 and IL13Rα2 had a rate exceeding 90% (191). The gene discussed is ERBB2; the disease is neoplasm.